March 16, 2017 07:42 AM EDT

Seres doubles down on a microbiome do-over as the FDA clears a make-or-break study

John Carroll

Editor & Founder

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

view job offer post your job now

TRENDING NOW

Lilly shuffles key executive positions; Mikael Dolsten takes another post-Pfizer assignment

Iovance stock plummets after lowered full-year guidance, missed analyst expectations for Amtagvi

Revolution’s KRAS drugs appear competitive in several lung cancer settings

AstraZeneca reports Phase 3 win for Imfinzi; Roche to build new manufacturing site in China

Chronic care startup Omada Health files to go public

sponsored

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges